$NKTX News
Last published 2d ago
- 2d agoNKTXNkarta Presents Initial Safety Data for NKX019 in 40 Patients Across Five Autoimmune Diseases at ACR Convergence 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced integrated safety results from 40 patients treated with NKX019, an allogeneic, off-the-shelf, CD19-directed CAR NK cell therapy candidate in its ongoing Ntrust clinic ...
- 3d agoNKTXNKX019 Clinical Update @ ACR Convergence 2026 - NKARTA INCEarnings Call TranscriptsGood day everyone. Welcome to NCARTA's webcast to review initial clinical data from the Entrust program being presented at ACR Convergence 2026. All webinar participants will be in a listen-only mode until the question a
- 4d agoNKTXNkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR ConvergenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Nkarta (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced positive initial clinical data from its Ntrust clinical trial program evaluating NKX019, its allogeneic, off-the-shelf CAR NK cell therapy candidate.
- 4d agoNKTXNkarta Announces Initial Clinical Data for NKX019 in Myositis and Systemic Sclerosis at ACR ConvergenceGlobeNewswireIn myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of
- 6d agoNKTXNkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered...
- 6d agoNKTXNkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026GlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases,
- 1w agoNKTXNkarta, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoNKTXNkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireInitial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026,
- 1w agoNKTXNkarta Reports Third Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswireInitial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence...
- 1mo agoNKTXNKARTA, INC. STIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - NKARTA INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel. And apologies for the late start. We're trying to get Nadir patched in, but he is available through Paul's phon
- 1mo agoNKTXSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - NKARTA INCEarnings Call TranscriptsAll right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel. And apologies for the late start. We're trying to get Nadir patched in, but he is available through Paul's phon
- 2mo agoNKTXNkarta to Participate in September Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 2mo agoNKTXNkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026GlobeNewswireTwo abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster
- 3mo agoNKTXNkarta Reports Second Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a
- 3mo agoNKTXCyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product DevelopmentGlobeNewswireParis, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda
- 4mo agoGTBPNKTXFATECMPX+1A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsPR NewswireDrug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ...
- 4mo agoNKTXNkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 5mo agoCMPXCRBUFATEGTBP+1After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellGlobeNewswireIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
- 5mo agoFATEGTBPIBRXIOVA+1Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetGlobeNewswireIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
- 5mo agoGTBPIBRXFATENKTX+1The $13 Million Company Teaching the Immune System to Hunt CancerPR NewswireUSA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)...
- 5mo agoGTBPFATENKTXIBRX+1Three TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesPR NewswireThe case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ...
- 6mo agoNKTXNkarta Reports First Quarter 2026 Financial Results and Corporate HighlightsGlobeNewswireEnrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient
- 7mo agoNKTXNkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersGlobeNewswireExpanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion
- 7mo agoNKTXNkarta to Participate in Needham Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 7mo agoNKTXNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsGlobeNewswireDose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical
- 8mo agoNKTXNkarta to Participate in March Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 11mo agoNKTXNkarta to Participate in Evercore Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 1y agoNKTXNkarta Reports Third Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireEnrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial
- 1y agoNKTXNkarta to Participate in November Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its
- 1y agoNKTXNkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 1y agoNKTXNkarta to Participate in a September Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its
- 1y agoNKTXNkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireInitial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations
- 1y agoNKTXNkarta to Participate in the H.C. Wainwright "HCW@Home" SeriesGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its
- 1y agoNKTXNkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune FocusGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
- 1y agoNKTXNkarta Reports First Quarter 2025 Financial Results and Corporate HighlightsGlobeNewswireEnrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include
- 1y agoNKTXNkarta to Participate in an April Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the
- 1y agoNKTXNkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate HighlightsGlobeNewswireDifferentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications
- 1y agoNKTXNkarta to Participate in March Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the
- 1y agoNKTXNkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2GlobeNewswireNtrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular
- 1y agoNKTXNkarta to Participate in an Upcoming Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the
- 2y agoNKTXNkarta to Participate in an Upcoming Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the
- 2y agoNKTXNkarta Reports Third Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswireFirst patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2 expected to initiate by year-end 2024 Preliminary clinical data
- 2y agoNKTXNkarta to Participate in Upcoming Investor ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the
- 2y agoNKTXNkarta Reports Second Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswireEnrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis, myositis and vasculitisPreliminary clinical data from Ntrust-1 and
- 2y agoNKTXNkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus ErythematosusGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at
- 2y agoNKTXNkarta Announces Leadership Updates, Appoints Nadir Mahmood as PresidentGlobeNewswireSOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership
- 2y agoNKTXNkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune IndicationsGlobeNewswirePatient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the
- 2y agoNKTXNkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies today announced that
- 2y agoENGNNAMSNKTXPCRX+1enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsBusiness WireenGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced
- 2y agoNKTXNkarta Reports First Quarter 2024 Financial Results and Corporate HighlightsGlobeNewswireDosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and